RBC Life Sciences Inc (RBCL) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of RBC Life Sciences Inc $0.00, price $0.00, upside +0.0%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch RBC Life Sciences Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $0.0001 – $1.00 · the $0.0007 price screens below the $0.0007 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow RBC Life Sciences in your weekly email
Every Wednesday you see whether RBC Life Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
RBC Life Sciences, Inc. manufactures, markets, and distributes nutritional supplements and personal care products. The company offers wellness products, weight loss, sports, and fitness products. RBC Life Sciences, Inc. is headquartered in Irving, Texas.
Stock analysis
RBC Life Sciences Inc (RBCL) currently trades at $0.0007, while our model-based Fair Value estimate is $0.0007, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of $0.0052 per share, and 1 of the 6 models we run sit above the $0.0007 price.
Bear case: the DCF Models group reads lowest at $0.0007, and 5 of the 6 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
RBC Life Sciences Inc reported revenue of $25.8M in FY2016 versus $25.2M in FY2012, a compound +0.6%/yr. Reported net income was −$756K in FY2016.
Key figures
Market cap $1.5K · Net margin −2.9% · Return on equity −6.8% · Return on assets (EBIT) −7.7% · Operating margin −21.2% · Revenue (TTM) $24.1M · Revenue growth (YoY) −28.1% · Free cash flow $6.7K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 250% above its 52-week low.
For context, the median of 10 Consumer Defensive peers we cover trades at −29% fair-value upside, at 0%, RBCL screens cheaper than that median.
Fair Value models
Bear $0.0007Fair Value $0.0007Bull $0.0007
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.16/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+5.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.0%
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
’05
’06
’07
’08
’09
’10
’11
’12
’13
’14
’15
’16
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−0.2% (2011) → −2.6% (2016)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2016 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 237 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score54 · Below median
Fair Value upside+0.0% · Above median
Profitability
Return on assets−10.0% · Bottom 25%
Net margin (TTM)−2.3% · Bottom 25%
Operating margin (TTM)−21.2% · Bottom 25%
Growth and dividend
Revenue growth−28.1% · Bottom 25%
Balance sheet
Debt / equity0.13× · Above median
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "RBC Life Sciences Inc Fair Value". https://www.fairvalue-calculator.com/stock/RBCL
Frequently asked questions
Is RBC Life Sciences Inc (RBCL) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0007 versus the last price from Sep 25, 2026 of $0.0007, about +0% upside (fairly valued).
What is the fair value of RBCL?
Our model-based fair value for RBC Life Sciences Inc is $0.0007 (as of Sep 27, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0007.
What is the quality score of RBCL?
RBC Life Sciences Inc has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for RBC Life Sciences Inc (RBCL)?
Our model-based price target is the fair value of $0.0007 (as of Sep 27, 2026) from 6 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the RBC Life Sciences Inc stock forecast for 2026?
Our models put fair value at $0.0007, about +0% upside versus the last price from Sep 25, 2026 of $0.0007 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of RBC Life Sciences Inc (RBCL)?
RBC Life Sciences Inc reported trailing-twelve-month revenue of about $24.1M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of RBC Life Sciences Inc (RBCL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For RBC Life Sciences Inc it is $0.0007 per share (as of Sep 27, 2026), against a price of $0.0007. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is RBC Life Sciences Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, RBCL trades below its calculated fair value: price $0.0007, fair value $0.0007, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RBCL?
No. The price is what the market pays today ($0.0007); the fair value is what the company's own numbers justify ($0.0007). For RBC Life Sciences Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is RBC Life Sciences Inc worth?
The market values RBC Life Sciences Inc at about $1.5K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0007; our models calculate a fair value of $0.0007 per share.
How solid is the balance sheet of RBC Life Sciences Inc (RBCL)?
Balance-sheet figures for RBC Life Sciences Inc (as of Sep 27, 2026): return on equity −6.8%, debt of 0.13 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is RBCL from its 52-week high?
RBC Life Sciences Inc trades at $0.0007, at its 52-week high of $0.0007 and 250% above the low of $0.0002 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0007 is for.
Which stocks are comparable to RBC Life Sciences Inc?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, Kenvue Inc, The Estée Lauder Companies Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is RBC Life Sciences Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0007, calculated fair value $0.0007 (+0%), Quality Score 54/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RBCL calculated?
We run RBC Life Sciences Inc through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0007, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. RBC Life Sciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of RBC Life Sciences Inc (RBCL)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0007. Our model-based fair value is $0.0007, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with RBC Life Sciences Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of RBC Life Sciences Inc
How large is the market capitalisation of RBC Life Sciences Inc (RBCL)?
The market capitalisation of RBC Life Sciences Inc is $1.5K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the net margin of RBC Life Sciences Inc (RBCL)?
The net margin of RBC Life Sciences Inc is −2.9% (fiscal year 2016). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of RBC Life Sciences Inc (RBCL)?
The return on equity (ROE) of RBC Life Sciences Inc is −6.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of RBC Life Sciences Inc (RBCL)?
On an EBIT basis the return on assets of RBC Life Sciences Inc is −7.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of RBC Life Sciences Inc (RBCL)?
The operating margin of RBC Life Sciences Inc is −21.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at RBC Life Sciences Inc (RBCL)?
Revenue at RBC Life Sciences Inc is growing −28.1% versus a year earlier (3y avg +0.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does RBC Life Sciences Inc (RBCL) generate?
The free cash flow of RBC Life Sciences Inc is $6.7K (fiscal year 2016). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does RBC Life Sciences Inc (RBCL) hold?
RBC Life Sciences Inc holds more cash than debt, $1.5M net (fiscal year 2016). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch RBC Life Sciences Inc in the live analysis
One click puts RBC Life Sciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026